Emerging therapy for the treatment of acute lymphoblastic leukemia

Expert Opinion on Emerging Drugs

Volumn 15, Issue 1, 2010, Pages 1-11

  Fullmer, Amber ^a   O'Brien, Susan ^a   Kantarjian, Hagop ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute lymphoblastic leukemia; Emerging treatment; Targeted therapy

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; ASPARAGINASE MACROGOL; CLOFARABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NELARABINE; NILOTINIB; PREDNISONE; RITUXIMAB; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CEREBELLUM DISEASE; DIARRHEA; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; FEVER; HAND FOOT SYNDROME; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; RASH; REVIEW; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

EID: 77749261179     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903456026     Document Type: Review

References (68)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29
2. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005;80:1517-27
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of acute leukemia. French-American-British Cooperative Group. Br J Haematol 1976;33:451-8
4. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49
5. WHO. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours, Volume 3. IARC Press, Lyon; p. 111-87
6. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783
7. Terstappen LWMM, Huang S, Picker LJ. Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow. Blood 1992;79:666
8. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia. Cancer 1999;86:1216-30
9. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113:3186-91
10. Fielding AK, Richards SM, Chora R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL 12/ECOG 2993 study. Blood 2007;109:944-50
11. Kantarjian HM, O'Brien S, Smith T, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin- dexamethasone (VAD) regimen. Br J Haematol 1994;88:94-100
12. Jones B, Freeman Aik, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-75
13. Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000; 88:1964-9
14. Ottman OG, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995;86:444-50
15. Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): efficacy and feasibility analysis with increasing dose levels. Blood 2008;112:Abstract 302
16. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamic and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744-50
17. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-31
18. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-61
19. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995;86:2091-7
20. Mahmoud DH Jr, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 1993;329:314-19
21. Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin Oncol 2004;31:702-13
22. Pui C-H, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003;349:640-9
23. Tucker J, Prior PF, Green CR, et al. Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukemia and lymphoma. Br J Cancer 1989;60:775
24. Pui C-H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology 2006:142-6
25. Rudnick SA, Cadman EC, Capizzi RL, et al. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979;44(4):1189-93
26. Capizzi RL, Yang JL, Cheng E, et al. Alteration of the pharmacokinetics of high-dose AraC by its metabolite, high araU in patients with acute leukemia. J Clin Oncol 1983;1:763-71
27. Hande KR, Stein RS, McDonough DA, et al. Effects of high-dose cytarabine. Clin Pharmacol Ther 1982;31:669-74
28. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987;5;2017-31
29. Wellwood J, Taylor K. Central nervous system prophylaxis in hematological malignancies. Int Med J 2002;32:252-8
30. Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult lymphoblastic leukemia. Ann Hematol 1996;72:194-201
31. Kantarjian HM, Walters RS, Smith TL, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988;72:1784-9
32. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD),adose-intensiveregimen,in adult acute lymphocytic leukemia. Cancer 2004;101:2788-801
33. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407
34. Thomas DA, Faderl S, Cortes J, et al. Update of the Hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 2004;104:748a
35. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1198-206
36. Yanada M, Ohno R, Naoe T. Recent advances in the treatment of Phildelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 2009;89:3-13
37. Ravandi F, Thomas D, Kantarjian H, et al. Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood 2008;112:Abstract 2921
38. Jabbour E, O'Brien S, Thomas DA, et al. Combination of the hyper-CVAD regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood 2058;112:Abstract 2919
39. Ottman OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood 2007;110:2815a
40. Thomas DA, Cortes J, Faderl S, et al. Hyper-CVAD and rituximab therapy in HIV-negative burkitt (BL) or burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (B-ALL). ASCO Annual Meeting Proc 2005;23:567s
41. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-70
42. Dworzak MN, Schumich AS, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008;112:3982-8
43. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remission in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007;109:5136-42
44. Faderl S, Thomas DA, Koller CA, et al. Hyper-CVAD plus nelarabine: a pilot study for patients with newly diagnosed T cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL). Blood 2008;112:Abstract 3960
45. O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 2008;113:2097-101
46. Faderl S, Estrov Z. The clinical significance of detection of residual disease in childhood ALL. Crit Rev Oncol Hematol 1998;28:31
47. Stock W, Estrov Z. Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1289
48. Gokbuget N, Kneba M, Raff T, et al. Risk-adapted treatment according to minimal residual disease in adult ALL. Best Pract Clin Haematol 2002;15:639-52
49. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002;10:1094-104
50. Foroni L, Coyle LA, Papaioannou M, et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment and response. Leukemia 1997;11:1732-41
51. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11(Suppl 1):S7-11
52. Jeha S, Razzouk BI, Rytting ME, et al. Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. Blood 2004;104:196a
53. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-73
54. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-86
55. Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 2007;7:113-18
56. McGregor BA, Brown AW, Osswald MB, Savona MR. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009;84:228-30
57. Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T-acute lymphoblastic leukemia. Yale J Biol Med 2006;79:169-72
58. Faderl S, Thomas DA, Garcia-Manero G, et al. Augmented hyper-CVAD in acute lymphoblastic leukemia (ALL): the MDACC experience with intensified L-asparaginase and vincristine in adult ALL salvage. Blood 2005;106:Abstract 1840
59. Faderl S, Thomas DA, Ravandi F, et al. Intensification of hyper-CVAD with L-asparaginase, vincristine, and dexamethasone ("augmented hyper-CVAD") has activity in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 2007;110:Abstract 4324
60. Esterhay RJ, Wiernik PH, Grove WR, et al. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood 1982;59:334-45
61. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG 2993). Blood 2008;111:1827-33
62. Ritchie E, Gore L, Roboz GJ, et al. Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia. Blood 2006;108:Abstract 1881
63. Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 2006;106:120-7
64. O'Brien S, Damon LE, Larson ML, et al. Early signs of tolerability and activity in a phase 2 study of weekly vincristine sulfate liposomal injection (VSLI, Marqibo) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in second relapse or progressing following two anti-leukemia treatment lines. Blood 2008;112:Abstract 3959
65. Thomas DA, Kantarjian HM, Stock W, et al. Phase 1 study of weekly vincristine sulfate (VCR) liposomes injection (VSLI, Marqibo") plus dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia (ALL). Blood 2008;112:Abstract 2930
66. Topp M, Goekbuget N, Kufer P, et al. Treatment with anti-CD19 BiTE antibody blinotumomab (MT103/MEDI-538) is able to eliminate minimal residual disease (MRD) in patient with B-precursor acute lymphoblastic leukemia (ALL): first results of an ongoing phase II study. Blood 2008;112:Abstract 1926
67. Goodall J, Squires MS, Lock V, et al. Outcome of aurora kinase inhibition of acute myeloid leukemia by AT9283 is dependent upon the presence or absence of mutations in type 1 ongogenetic kinase signaling pathways. Blood 2008;112:Abstract 1613
68. Teachey DT, Sheen C, Jall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008;112:2020-3